NCT00858572 2014-09-18STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative DisordersSynta Pharmaceuticals Corp.Phase 1 Completed31 enrolled
NCT00964873 2014-09-18A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaSynta Pharmaceuticals Corp.Phase 1 Completed29 enrolled